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Abstract 
Background: Lithium is considered the gold standard treatment for bipolar disorder (BD). Current clinical guidelines 
and scientific evidence support its use as a first‑line treatment in BD. However, over the last two decades, there has 
been a downward tendency in lithium’s use in several developed countries. Based on a nationwide survey, this study’s 
objective is to analyze in a large sample of psychiatrists relevant issues of the use of lithium salts in BD.
Methods: Data were collected through an anonymous survey sent by email among 500 psychiatrists who belong to 
a National Society of Psychiatry (Spanish Society of Biological Psychiatry). The survey is a self‑administered question‑
naire consisting of 21 items on the most key aspects of lithium’s use (indication, dosage, monitoring, and information 
for patients).
Results: 212 psychiatrists completed the survey. 70% of psychiatrists prescribe lithium to more than 50% of patients 
diagnosed with BD. Adverse effects are the main reason not to use lithium salts. Over 75% of the participants consider 
lithium salts the treatment of choice for the maintenance phase of BD, both in women and men. Most of the partici‑
pants (> 50%) start lithium after the first affective episode, use conservative plasma concentrations (0.6–0.8 mmol/L), 
and generally prescribe it twice a day. 57% of psychiatrists who treat patients under 18 do not use lithium in this 
population. About 70% of the survey respondents use official protocols to inform and monitor patients on lithium 
treatment.
Conclusions: From the results of the present study, it can be concluded that the use of lithium in Spain is in line with 
the recommendations of the main international clinical guidelines and current scientific literature. The first reason not 
to prescribe lithium in our country is the perception of its adverse effects and not the aspects related to its practical 
use or its effectiveness. Considering that BD is a chronic disease with a typical onset in adolescence, the low rate of 
prescription of lithium salts in patients under 18 must be thoroughly studied.
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Introduction
Even though more than 70  years have passed since the 
Australian psychiatrist John Cade reported the antimanic 
efficacy of lithium carbonate (Cade 1949), the main cur-
rent clinical guidelines still consider it a first-choice 
treatment for Bipolar Disorder (BD) (Fountoulakis et al. 
2017; Yatham et al. 2018). It has proved useful not only 
in acute manic episodes (Yildiz et  al. 2014) but also in 
depressive (Baldessarini et  al. 2020; Malhi et  al. 2017) 
and mixed episodes (Sani and Fiorillo 2019). Neverthe-
less, lithium is noted for its outstanding efficacy in the 
maintenance or prophylactic treatment of BD (Jauhar 
and Young 2019; Severus et al. 2018). Bearing in mind the 
frequent chronic, recurrent and disabling nature of BD 
(a disease that affects more than 1% of the world popu-
lation) (Vieta et al., 2018), a long-term treatment which 
Open Access
*Correspondence:  xabier.perezdemendiolaetxezarraga@osakidetza.eus
1 Bioaraba, Research Group on Severe Mental Illness; Osakidetza, Araba 
University Hospital, Psychiatry Service; Faculty of Medicine, Department 
of Neurosciences, University of the Basque Country UPV / EHU, 
Vitoria‑Gasteiz, Spain
Full list of author information is available at the end of the article
Page 2 of 8Pérez de Mendiola et al. Int J Bipolar Disord            (2021) 9:10 
allows preventing relapses or recurrences is vital. In this 
regard, lithium continues to be the gold standard treat-
ment supported by extensive scientific evidence (Car-
valho et  al., 2020). Both in controlled clinical trials and 
observational studies, lithium has shown its efficacy and 
superiority in the prophylaxis of any type of affective epi-
sode (Berk et al. 2017; González-Pinto et al. 2018; Kess-
ing et al. 2018; Lähteenvuo et al. 2018; Miura et al. 2014; 
Severus et al. 2014).
In addition to its mood-stabilizing properties, lithium 
has a distinctive, independent, and proven anti-suicide 
action (Barjasteh-Askari et al. 2020; González-Pinto et al. 
2006; Smith and Cipriani 2017; Song et al., 2017). This is 
a relevant quality in BD since up to 15% of patients diag-
nosed with BD die by suicide (Gordovez and McMahon 
2020). In fact, a systematic review and meta-analysis 
showed that treatment with lithium among people with 
mood disorders could reduce the risk of death and sui-
cide up to 60% compared to placebo (Cipriani et  al. 
2013). Remarkable neuroprotective and antiviral proper-
ties have also been attributed to lithium (Post 2018; Ryba-
kowski 2018; Murru et al. 2020; Van Gestel et al. 2019). 
It slows brain aging (Van Gestel et al. 2019) and reduces 
the risk of dementia by almost 50% in patients with BD 
(Velosa et al. 2020). It could also attenuate the cognitive 
and functional decline in patients (without BD) with mild 
cognitive impairment (Forlenza et  al. 2019). Moreover, 
the use of lithium has recently been proposed as a poten-
tial treatment for CoViD-19 (Murru et al. 2020).
Despite the undeniable evidence in favor of its appli-
cation in BD, a descendent tendency in the use of lith-
ium has been noticed in the US (Rhee et al. 2020) and in 
numerous European countries (Bohlken et al. 2020; Kar-
anti et  al., 2016; Kessing et  al., 2016; Lyall et  al., 2019). 
In several of them, it has changed from being the most 
prescribed drug to the least one, even behind the contro-
versial antidepressants. (Kessing et al., 2016; Lyall et al., 
2019). The emergence of new effective drugs for BD, such 
as second-generation antipsychotics and certain antie-
pileptics, has overturned the prescription pattern of BD 
(Malhi et al., 2020; Anmella et al., 2020). The absence of 
pharmaceutical marketing, the toxic perception of its 
adverse effects, the slow onset of action and the need 
for venipuncture monitoring are some of the possible 
causes of this declining trend (Gitlin, 2016a; Rybakowski, 
2018). Neither the main clinical guidelines nor current 
scientific literature supports the idea of replacing lithium 
with other drugs. In fact, over the last two decades, the 
decrease in lithium’s use is not widespread, and in certain 
countries, lithium’s prescription rate has remained high. 
In some countries, more than 50% of bipolar patients are 
treated with lithium, while in the US, for example, only 
17% (Kessing  2019; Parabiaghi et  al. 2015; Renes et  al. 
2018; Rhee et al. 2020) (Table 1).
Table 1 Changes in the lithium prescription rate in several European countries over the last two decades
Study Country Period Data source Results
Bohlken et al. 2020 Germany 2009–2018 Neuropsychiatric private practices’ records The percentage of patients with bipolar disorder 
receiving lithium declined from 31,4% (2009) 
to 26,2% (2018)
Rhee et al. 2020 United States 1997–2000 
vs. 2013–
2016
Outpatient physician reports of patient visits The percentage of patients with bipolar dis‑
order receiving lithium declined from 30,4% 
(1997–2000) to 17,6% (2013–2016)
Lyall et al. 2019 Scotland 2009–2016 Records of outpatient clinic attendance, 
general/acute hospital admissions and 
psychiatric hospital admissions
The percentage of patients with bipolar disorder 
receiving lithium declined from 26% (2009) to 
22% (2016)
Renes et al. 2018 Netherlands 2009–2014 Outpatient psychiatrists’ and patients’ surveys Lithium was used by 70% of patients with 
bipolar disorder or schizoaffective disorder, 
bipolar type
Karanti et al. 2016 Sweden 2007–2013 Records of private and public psychiatric 
outpatient health care units
The percentage of patients with bipolar disorder 
receiving lithium declined from 51% (2007) to 
41% (2013)
Kessing et al. 2016 Denmark 2000–2011 Records of all Danish patients with a first‑ever 
contact with mental healthcare
The one‑year prescription rate of lithium in 
bipolar patients decreasedfrom 41% (2000) to 
34% (2011)
Parabiaghi et al. 2015 Italy 2000–2010 A population‑based database of dispensing 
records
The prevalence of lithium treatment grew by 
38% duringthe observation period
Hayes et al. 2011 England 1995–2009 Records of primary care patients The prescriptionrate for lithium increased from 
22.5% (1995) to 29.3% (2009)
Castells et al. 2006 Spain 1985–2003 Pharmacy sales data of medicinal products Lithium daily dose per 1000 inhabitants per day 
(DID) increased from 0.21 (1985) to 0.79 (2003)
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In this context, an anonymous survey was carried 
out among psychiatrists. The primary objective of this 
study was to evaluate the use and current perception 
of lithium’s treatment on the most relevant aspects of 
the drug: indication, dosage, monitoring, and informa-
tion for patients. The results presented below could be 
used to elaborate new consensus or national protocols, 




Between 11 May and 11 July 2020, an anonymous 
online survey was conducted on the use of lithium, 
thanks to the support of the Spanish Society of Bio-
logical Psychiatry (SEPB). All the members of the SEPB 
(500 psychiatrists) received an email in which they were 
informed about the purpose of the study. They were 
invited to participate in it by completing the question-
naire attached to the same message. The collaboration 
was voluntary, and responses were recorded, elimi-
nating the identity of the participants. Two reminder 
emails were sent during the mentioned period to maxi-
mize the response rate. The survey was created and 
performed with Google Forms, and Microsoft Office 
Excel 2019 was used for the analysis and representa-
tion of the data. The study was approved by the Clini-
cal Research Ethics Committee of the Araba University 
Hospital (Spain).
Questionnaire
The survey was designed to obtain a general perspective 
on lithium’s use from a sample of Spanish psychiatrists. 
In order to encourage participation, a brief self-admin-
istered questionnaire (21 items) with multiple-choice 
questions (Additional file  1: Appendix S1) was elabo-
rated. The first 5 questions are related to demography: 
age, sex, and origin of the respondents. The following 
3 points address the prescription rate of lithium in BD 
and the main reasons not to prescribe it. The next 5 
requests explore its status compared to the rest of the 
drugs and the stage in the course of the illness when 
lithium is usually introduced. Subsequently, there are 
2 specific questions about two practical and relevant 
aspects of lithium’s use: plasma concentrations and 
dose distribution. The next 4 refer to the use of lithium 
in special clinical circumstances (minors, elderly and 
psychiatric comorbidity). The final issues are about the 
availability of official documents or protocols to moni-
tor and inform patients undergoing lithium treatment.
Analysis
Data are analyzed using descriptive statistics. The results 
are represented by graphs based on percentages and 
absolute numbers using Microsoft Office Excel 2019.
Results
Demographics
A total of 212 responses are obtained from almost all 
Spain regions (Additional file 1: Appendix S2. Figure S1). 
The majority of respondents (86%) come from Catalonia 
(28%), the Community of Madrid (27%), Basque Country 
(15%), Andalusia (8%), and Valencian Community (8%). 
The distribution between sexes and age groups is practi-
cally homogeneous as it is the percentage of professionals 
who work at hospitals (psychiatric or general) and outpa-
tient settings (Table 2).
Lithium’s prescription and reasons not to use it
Only 3% of respondents never prescribe lithium salts. 
70% of participants prescribe lithium to more than 50% 
of patients diagnosed with BD and 20% to more than 75% 
of them (Additional file 1: Appendix 2. Figure S2).
Almost 62% of psychiatrists affirm that the main reason 
not to prescribe lithium is its side effects. A significantly 
lower percentage of specialists state that the leading 
cause not to prescribe it is the rejection by the patient 
(13%) and the need for monitoring by venipuncture (10%) 
(Fig. 1).
Over 75% of the participants choose lithium as the 
first option in the maintenance treatment of BD, both in 
women and men (Additional file 1: Appendix S2. Figure 
S3). As a second option, antipsychotics (34%) and val-
proate (31%) stand out in women. For men, valproate 
(64%) is clearly the second preferred option.
Table 2 Demographic profile of the participants









> 65 20 (9%)
Work center
General hospital 88 (41%)
Psychiatric hospital 23 (11%)
Outpatient consultation 101 (48%)
Total 212 (100%)
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Finally, more than 80% of respondents usually initi-
ate treatment with lithium salts after the first affective 
episode. Most of them prescribe it after the first manic 
episode. More than 25% of psychiatrists, when there is 
a family history of BD, tend to start lithium treatment 
after the first depressive episode (Additional file  1: 
Appendix S2. Table S1).
Serum levels and dose distribution
50% of the participants use serum lithium levels 
between 0.6 and 0.8  mmol/L for the maintenance 
phase of BD. 21% consider adequate any concentration 
within the therapeutic range established between 0.6 
and 1.2  mmol/L. Another 20% utilizes higher lithium 
serum levels between 0.8 and 1  mmol/L to prevent 
relapse or recurrence in BD (Fig. 2).
Regarding the distribution of the lithium dose, more 
than 75% of psychiatrists prescribe it in 2 daily doses. 
13% in 3 daily doses and only 9% in a single daily dose 
(Fig. 2).
Specific populations
60% of respondents (128) do not deal with children and 
adolescents. Among the psychiatrists who care for under-
age BD patients, most (57%) do not use lithium salts in 
this population (Additional file 1: Appendix S2. Table S2). 
By contrast, the majority of survey respondents do use 
lithium in older age BD (Additional file 1: Appendix S2. 
Table S2).
Over 80% of specialists do not have any trouble pre-
scribing lithium to patients with a comorbid Substance 
Use or a Personality Disorder (Additional file 1: Appen-
dix S2. Table S2).
Information for patients and monitoring protocols
One-third of psychiatrists who prescribe lithium do 
not have documentation for patients at their workplace. 
Furthermore, a quarter of respondents do not follow a 
formal protocol for monitoring lithium and its adverse 
effects (Additional file 1: Appendix S2. Figure S4).
Discussion
This is the first study referring to the use of lithium that 
analyzes psychiatrists’ current general perspective. In 
2018, an interesting international survey was published 
focused exclusively on lithium monitoring (Nederlof 
et  al. 2018). In order to understand the international 
framework of lithium’s underuse, it is essential to know 
the specialists’ point of view (Malhi et al. 2020).
According to the National survey results on the use of 
lithium, the vast majority of Spanish psychiatrists in this 
sample, which includes professionals from all the autono-
mous communities, comply with the recommendations 
of the latest clinical guidelines and the scientific litera-
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Fig. 2 The preferred serum level and dose distribution of lithium
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more than 50% of patients diagnosed with BD and 20% 
to over 75%. In this line, more than 75% of national psy-
chiatrists who participated in this study chose lithium as 
their first-choice treatment in the maintenance phase of 
BD both in men and women.
The apparently high lithium’s prescription by Spanish 
psychiatrists agrees with the recently observed results in 
the Netherlands, where 70% of patients diagnosed with 
BD or Schizoaffective Disorder were treated with lith-
ium (Renes et al. 2018). Nevertheless, as it is mentioned 
above, this percentage is significantly higher than in other 
neighboring countries (Kessing 2019). In Sweden, the 
prescription rate for lithium in BD is 55%, in Denmark 
41.7%, in Germany 26.2%, and in Scotland 22% (Bohlken 
et al. 2020; Karanti et al. 2016; Kessing et al. 2016; Lyall 
et al. 2019) (Table 1).
In the current study, we asked participants about the 
reasons not to prescribe lithium in the long-term treat-
ment of BD. Most agree that lithium’s adverse effects 
are the main barrier to its use. Only 6% of the partici-
pants believe that lithium’s non-prescription is due to 
the availability of other more effective mood stabilizers. 
This fact shows the conviction that participating psychia-
trists have in the efficacy of lithium above other effective 
drugs. Practical aspects related to lithium’s use, such as 
the need for monitoring or the slow onset of action, are 
not considered obstacles for the drug’s prescription. As 
suggested for clozapine (Bachmann et al. 2017; Verdoux 
et al. 2018), the high use of lithium in Spain could be the 
consequence of a local "culture" that favors the use of the 
drug. This could be because of the transmission of per-
sonal experience from expert therapists to beginners, 
institutional support that facilitates the adequate infra-
structure for patients’ follow-up on lithium treatment 
(lithium clinics and national registries, for example), and 
the promotion of its use by scientific societies. Know-
ing exactly why lithium is not prescribed in other coun-
tries would help to understand better its international 
underuse.
Despite the fact that most of the professionals believe 
that lithium’s side effects are the main limiting fac-
tor for its prescription, more than 75% consider it the 
first-choice treatment for the maintenance therapy of 
BD for both women and men. In recent years, it has 
been confirmed that the most severe adverse effects 
of lithium, that is, kidney dysfunction and teratogenic 
risk, were overestimated in the former reports (Fornaro 
et al. 2020; Nielsen et al. 2017). Additionally, the risk of 
suffering from both complications can be minimized by 
using a minimum effective dose and close monitoring 
of plasma levels (Tondo et  al. 2019). To avoid making 
the survey extensive and more challenging to answer, 
we decided not to ask about the short- and long-term 
adverse effects of lithium in the current study, although 
we did consider it. Now that we know this result, it 
would be interesting to conduct a new survey in the 
future, focusing on the adverse effects of lithium and its 
management.
Therapeutic alternatives to lithium are not exempted 
from significant risks. Valproate has a high teratogenic 
risk, discouraging its use in women of childbearing age 
(European Medicines Agency 2018; Anmella et al. 2019). 
That is why it is striking the relatively high percentage 
of psychiatrists (31%) who choose valproate as a sec-
ond option for women suffering from BD. On the other 
hand, antipsychotics are associated with a more signifi-
cant weight gain and a worse metabolic profile than lith-
ium (Hayes et al. 2016; Jauhar and Young 2019). Besides, 
they can cause extrapyramidal and sexual symptoms, 
too (Huhn et al. 2019). Although it is clear that there is 
a reasonable concern about its negative effects, these 
data would explain the high percentage of psychiatrists 
who choose lithium as the first option for the long-term 
treatment of BD in both sexes. Moreover, lithium has 
potential long-term benefits related to neurogenesis that 
are being studied (Berk et al. 2017; Forlenza et al., 2019; 
Sun et  al., 2019; Zanni et  al., 2019; Ciftci et  al. 2020). 
Emphasizing the benefits of lithium without forgetting 
its adverse effects (Gitlin 2016b; Tondo et al. 2017) could 
help improve the outcome of patients with BD.
The most used serum lithium levels for the mainte-
nance treatment of BD (0.6–0.8 mmol/L) are also in line 
with current scientific advice (Nolen et al. 2019). This is 
a crucial issue because the use of conservative plasma 
levels could prevent lithium intoxication, renal, and cen-
tral nervous system adverse effects (Nielsen et  al. 2018; 
Schoot et al. 2019). Another practice that could minimize 
the risk of renal impairment is the schedule of a single 
lithium daily dose (Schoot et al. 2019). However, this reg-
imen is the least used among the respondents who prefer 
to distribute lithium dosage in 2 or 3 daily doses.
Another point that differs from the latest scientific 
publications is the little use of lithium among children 
and adolescents with BD. Most psychiatrists who take 
care of minors (57%) do not use lithium when the litera-
ture suggests that it is an effective and safe treatment in 
this population (Amerio et al. 2018; Hafeman et al. 2019). 
Considering that the typical onset of the disease is in 
adolescence, and due to the dividing line between child 
and adult care in Spain, it can be challenging to supply 
lithium since the first episode.
Finally, it must be stated that the availability of official 
documentation on lithium for patients (67%) and proto-
cols for its monitoring (72%) is similar to the mentioned 
international study (Nederlof et al. 2018). The publication 
of expert consensuses, such as the one which has recently 
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been prepared by the SEPB (González-Pinto et al. 2021), 
is an initiative that can improve these figures.
This study has several strengths and limitations. As 
underlined before, this is the first research that evaluates 
the general perspective on lithium’s use among a large 
group of psychiatrists. The fact that 86% of the responses 
come from 5 autonomous communities limits the gener-
alization of the results to the whole country. Nonetheless, 
they are 5 of the most populated autonomous commu-
nities, representing 64% of the Spanish population. So, 
this is a somewhat expected finding. Furthermore, these 
5 regions attract specialists trained in other territories 
because of their greater job offer. The number (212) and 
the rate (42.5%) of responses are higher or similar to 
other surveys addressed to professionals (Campos et  al. 
2020; Daod et al. 2019; Nederlof et al. 2018). The social 
desirability and selection bias could have overestimated 
the use of lithium in our country. The survey was distrib-
uted only among members of a single national society of 
Psychiatry, not considering the perspective of psychia-
trists who are not members of the SEPB. As part of SEPB, 
members might be exposed to a more continuous update 
and training on guidelines due to the continuous educa-
tion and training opportunities offered within the soci-
ety. Research participants could have chosen the most 
socially desirable or acceptable responses rather than 
responses that reflected their true thoughts or practices. 
However, the anonymous nature of the survey could have 
favored obtaining honest and real answers.
Finally, the present study does not analyze national 
prescription registers. Thus, it would be interesting to 
complement the current essay with a pharmaco-epide-
miological analysis, such as those carried out in other 
countries that have already been pointed out (Table  1). 
Nevertheless, it should be noted that the results obtained 
in this study are congruent with the pharmaco-epidemi-
ological research performed in other countries (Parabi-
aghi et al. 2015; Renes et al. 2018) and with the only one 
published in Spain (Castells et  al. 2006). In a forthcom-
ing paper, it would also be interesting to explore lithium’s 
use in the acute phases (mania, depression, and mixed 
states). Its efficacy and role are different from the main-
tenance phase and vary across the distinct acute phases 
(Baldessarini et  al. 2020; Malhi et  al. 2017). Moreover, 
most recent guidelines state that clinicians should con-
sider the maintenance phase when selecting acute phase 
treatments (Yatham et al. 2018).
Conclusions
This survey results suggest that, at least in Spain, the use 
of lithium is consistent with the latest clinical guidelines. 
Based on these results, except for children and adoles-
cents, one cannot speak of an underuse of lithium in 
Spain. The use of valproate as one of the main alterna-
tives to lithium in women is one of the few matters that 
differ from the recommendations of the main scientific 
societies. The main barrier to prescribe lithium is its side 
effect profile. Behind this apparent high use of lithium 
could be a local culture that favors the dissemination of 
scientific and practical information about the drug.
Supplementary Information
The online version contains supplementary material available at https ://doi.
org/10.1186/s4034 5‑020‑00215 ‑z.
Additional file 1: Appendix S1. The questionnaire. Appendix S2: Com‑




The authors want to acknowledge the Center for Biomedical Research in 
Mental Health (CIBERSAM), Carlos III Health Research Institute, the Basque 
Government, and the University of the Basque Country (UPV/EHU).
Authors’ contributions
XPM and AG‑P performed the survey, analyzing, writing, and editing the data. 
DH‑M and EV provided a critical appraisal of the manuscript. All authors read 
and approved the final manuscript.
Funding
This work was supported by Carlos III Health Research Institute [Grant Number 
PI18/0155] (co‑financed by the European Regional Development Fund 
(FEDER/ERDF)/European Social Fund ’Investing in your future’); Networking 
Center for Biomedical Research in Mental Health (CIBERSAM), the Basque 
Government [Grant number, 2017111104] and the University of the Basque 
Country [Grant Number 321212ELBY]. The psychiatric research department 
in Araba University Hospital is supported by the Stanley Research Foundation 
[Grant number 03‑RC‑003]..
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of Basque Country 
(Spain).
Consent for publication
Respondents authorized the use of their data based on current legislation on 
the protection of personal data.
Competing interests
EV has received grants and served as consultant, advisor, or CME speaker 
unrelated to the present work for the following entities: AB‑Biotics, Abbott, 
Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, 
Janssen, Lundbeck, Otsuka, Sage, Sanofi‑Aventis, Sunovion, and Takeda. The 
other authors do not report any financial or other relationship relevant to the 
subject of this article.
Author details
1 Bioaraba, Research Group on Severe Mental Illness; Osakidetza, Araba Univer‑
sity Hospital, Psychiatry Service; Faculty of Medicine, Department of Neuro‑
sciences, University of the Basque Country UPV / EHU, Vitoria‑Gasteiz, Spain. 
2 Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, 
Centre for Biomedical Research Network on Mental Health (CIBERSAM), 
Barcelona, Spain. 
Page 7 of 8Pérez de Mendiola et al. Int J Bipolar Disord            (2021) 9:10  
Received: 10 October 2020   Accepted: 27 November 2020
References
Amerio A, Ossola P, Scagnelli F, et al. Safety and efficacy of lithium in children 
and adolescents: a systematic review in bipolar illness. Eur. Psychiatry. 
2018;54:85–97.
Anmella G, Pacchiarotti I, Cubała WJ, Dudek D, Maina G, Thomas P, Vieta 
E. Expert advice on the management of valproate in women with 
bipolar disorder at childbearing age. Eur Neuropsychopharmacol. 
2019;29(11):1199–212.
Anmella G, Vieta E, Hidalgo‑Mazzei D. Commentary on: “Make lithium great 
again!” Bipolar Disord. 2020. https ://doi.org/10.1111/bdi.12998 .
Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine 
use: a study in 17 countries. Acta Psychiatr Scand. 2017;136:37–51.
Baldessarini RJ, Vazquez GH, Tondo L. Bipolar depression: a major unsolved 
challenge. Int J Bipolar Disord. 2020;8(1):1.
Barjasteh‑Askari F, Davoudi M, Amini H, Ghorbani M, Yaseri M, Yunesian M, et al. 
Relationship between suicide mortality and lithium in drinking water: a 
systematic review and meta‑analysis. J Afect Disord. 2020;264:234–41.
Berk M, Dandash O, Daglas R, Cotton SM, Allott K, Fornito A, Suo C, Klauser 
P, Liberg B, Henry L, Macneil C, Hasty M, McGorry P, Pantelis C, Yücel M. 
Neuroprotection after a first episode of mania: a randomized controlled 
maintenance trial comparing the effects of lithium and quetiapine on 
grey and white matter volume. Transl Psychiatry. 2017;7(1):e1011.
Bohlken J, Bauer M, Kostev K. Drug treatment for patients with bipolar disor‑
ders in psychiatric practices in Germany in 2009 and 2018. Psychiatry Res. 
2020;289:112965.
Cade JFK. Lithium salts in the treatment of psychotic excitement. Med J Aust. 
1949;36:349–52.
Campos P, Carrió M, Vicedo A, Bioque M. Actitud de los psiquiatras respecto al 
uso de olanzapina en la práctica clínica: una encuesta nacional. Psiquiat‑
ría Biológica. 2020;27:3–8.
Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58–66.
Castells X, Vallano A, Rigau D, et al. Trends in lithium prescription in Spain 
from1985 to 2003. J Affect Disord. 2006;91:273–6.
Ciftci E, Karacay R, Caglayan A, Altunay S, Ates N, Altintas MO, Doeppner TR, 
Yulug B, Kilic E. Neuroprotective effect of lithium in cold‑ induced trau‑
matic brain injury in mice. Behav Brain Res. 2020;17(392):112719.
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of 
suicide in mood disorders: updated systematic review and meta‑analysis. 
BMJ. 2013;2013(346):f3646.
Daod E, Krivoy A, Shoval G, Zubedat S, Lally J, Vadas L, et al. Psychiatrists’ 
attitude towards the use of clozapine in the treatment of refractory 
schizophrenia: a nationwide survey. Psychiatry Res. 2019;275:155–61.
European Medicines Agency (EMA). New measures to avoid valproate expo‑
sure in pregnancy endorsed. EMA/375438/2018.
Forlenza OV, Radanovic M, Talib LL, Gattaz WF. Clinical and biological effects of 
long‑term lithium treatment in older adults with amnestic mild cognitive 
impairment: randomised clinical trial. Br J Psychiatry. 2019;5:1–7.
Fornaro M, Maritan E, Ferranti R, Zaninotto L, Miola A, Anastasia A, et al. Lithium 
exposure during pregnancy and the postpartum period: a systematic 
review and meta‑analysis of safety and efficacy outcomes. Am J Psychia‑
try. 2020;177(1):76–92.
Fountoulakis KN, Grunze H, Vieta E, Young A, Yatham L, Blier P, et al. The 
International College of Neuro‑Psychopharmacology (CINP) treatment 
guidelines for bipolar disorder in adults (CINP‑BD‑2017), Part 3: the clini‑
cal guidelines. Int J Neuropsychopharmacol. 2017;20:180–95.
Gitlin M. Why is lithium not prescribed more often? Here are the reasons. J 
Psychiatry Neurol Sci. 2016a;29:293–7.
Gitlin MJ. Lithium side effects and toxicity: prevalence and management 
strategies. Int J Bipolar Disord. 2016b;4:27.
González‑Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder 
patients and adherence to long‑term lithium treatment. Bipolar Disord. 
2006;8:618–24.
González‑Pinto A, López‑Peña P, Bermúdez‑Ampudia C, Vieta E, Martinez‑
Cengotitabengoa M. Can lithium salts prevent depressive episodes in the 
real world? Eur Neuropsychopharmacol. 2018;28(12):1351–9.
González‑Pinto A, Balanzá‑Martínez V, Benabarre Hernández A, et al. Consenso 
de expertos sobre propuestas de información al paciente en tratamiento 
con sales de litio. Revista de Psiquiatría y Salud Mental. 2021;14:27–39.
Gordovez FJA, McMahon FJ. The genetics of bipolar disorder. Mol Psychiatry. 
2020;25:544–59.
Hafeman DM, Rooks B, Merranko J, Liao F, Gill MK, Goldstein TR, et al. 
Lithium versus other mood stabilizing medications in a longitudinal 
study of bipolar youth. J Am Acad Child Adolesc Psychiatry. 2019, 
S0890–8567(19)31399‑1.
Hayes J, Prah P, Nazareth I, et al. Prescribing trends in bipolar disorder: cohort 
study in the United Kingdom THIN primary care database 1995–2009. 
PLoS One. 2011;6:e28725.
Hayes JF, Marston L, Walters K, Geddes JR, King M, Osborn DP. Lithium vs. 
valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for 
bipolar disorder: a population‑based UK cohort study using electronic 
health records. World Psychiatry. 2016;15:53–8.
Huhn M, Nikolakopoulou A, Schneider‑Thoma J, et al. Comparative efficacy 
and tolerability of 32 oral antipsychotics for the acute treatment of adults 
with multi‑episode schizophrenia: a systematic review and network 
meta‑analysis. Lancet. 2019;394:939–51.
Jauhar S, Young AH. Controversies in bipolar disorder; role of second‑
generation antipsychotic for maintenance therapy. Int J Bipolar Disord. 
2019;7(1):10.
Karanti A, Kardell M, Lundberg U, Landén M. Changes in mood stabilizer pre‑
scription patterns in bipolar disorder. J Affect Disord. 2016;195:50–6.
Kessing L. Lithium as the drug of choice for maintenance treatment in bipolar 
disorder. Acta Psychiatr Scand. 2019;140(2):91–3.
Kessing LV, Vradi E, Andersen PK. Nationwide and population‑based prescrip‑
tion patterns in bipolar disorder. Bipolar Disord. 2016;18:174–82.
Kessing LV, Bauer M, Nolen WA, Severus E, Goodwin GM, Geddes J. Effective‑
ness of maintenance therapy of lithium vs. other mood stabilizers in 
monotherapy and in combinations: a systematic review of evidence from 
observational studies. Bipolar Disord. 2018;20:419–31.
Lahteenvuo M, Tanskanen A, Taipale H, et al. Real‑world effectiveness of phar‑
macologic treatments for the prevention of rehospitalization in a finnish 
nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 
2018;75(4):347–55.
Lyall LM, Penades N, Smith DJ. Changes in prescribing for bipolar disorder 
between 2009 and 2016: national‑level data linkage study in Scotland. Br 
J Psychiatry. 2019;215(1):415–21.
Malhi GS, Gessler D, Outhred T. Use of lithium for treatment of bipolar disorder: 
recommendations from clinical practice guidelines. J Affect Disord. 
2017;217:266–80.
Malhi GS, Bell E, Boyce P, Hazell P, Murray G, Bassett D, Bryant RA, Hopwood 
M, Lyndon B, Mulder R, Porter RJ, Singh A, Gershon S. Make lithium great 
again! Bipolar Disord. 2020;22(4):325–7.
Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, 
Motomura K, Shimano‑Katsuki S, Leucht S, et al. Comparative efficacy and 
tolerability of pharmacological treatments in the maintenance treatment 
of bipolar disorder: a systematic review and network meta‑analysis. 
Lancet Psychiatry. 2014;1:351–9.
Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G, Schulze TG, 
et al. International group for the study of lithium treated, lithium’s anti‑
viral effects: a potential drug for CoViD‑19 disease? Int J Bipolar Disord. 
2020;8:21.
Nederlof M, Heerdink ER, Egberts ACG, et al. Monitoring of patients treated 
with lithium for bipolar disorder: an international survey. Int J Bipolar 
Disord. 2018;6:12.
Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, et al. What is the 
optimal serum level for lithium in the maintenance treatment of bipolar 
disorder? A systematic review and recommendations from the ISBD/IGSLI 
Task Force on treatment with lithium. Bipolar Disord. 2019;21:394–409.
Parabiaghi A, Barbato A, Risso P, Fortino I, Bortolotti A, Merlino L, et al. Lithium 
use from 2000 to 2010 in Italy: a population‑based study. Pharmacopsy‑
chiatry. 2015;48:89–94.
Post RM. The new news about lithium: an underutilized treatment in the 
United States. Neuropsychopharmacology. 2018;43:1174–9.
Renes JW, Regeer EJ, Hoogendoorn AW, Nolen WA, Kupka RW. A nationwide 
study on concordance with multimodal treatment guidelines in bipolar 
disorder. Int J Bipolar Disord. 2018;6:22.
Page 8 of 8Pérez de Mendiola et al. Int J Bipolar Disord            (2021) 9:10 
Rhee TG, Olfson M, Nierenberg AA, et al. 20‑Year trends in the pharmacologic 
treatment of bipolar disorder by psychiatrists in outpatient care settings. 
Am J Psychiatry. 2020;177:706–15.
Rybakowski JK. Challenging the negative perception of lithium and optimizing 
its long‑term administration. Front Mol Neurosci. 2018;11:349.
Sani G, Fiorillo A. The use of lithium in mixed states. CNS Spectr. 2019. https ://
doi.org/10.1017/S1092 85291 90011 84.
Schoot TS, Molmans THJ, Grootens KP, Kerckhoffs APM. Systematic review and 
practical guideline for the prevention and management of the renal side 
effects of lithium therapy. Eur Neuropsychopharmacol. 2019;31:16–32.
Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes 
in bipolar disorders: Systematic review and meta‑analysis. Int J Bipolar 
Disord. 2014;2:15.
Severus E, Bauer M, Geddes J. Efficacy and effectiveness of lithium in the 
longterm treatment of bipolar disorders: an update 2018. Pharmacopsy‑
chiatry. 2018;51(5):173–6.
Smith KA, Cipriani A. Lithium and suicide in mood disorders: updated meta‑
review of the scientific literature. Bipolar Disord. 2017;19:575–86.
Song J, Sjölander A, Joas E, Bergen SE, Runeson B, Larsson H, et al. Suicidal 
behavior during lithium and valproate treatment: a within‑individual 
8‑year prospective study of 50,000 patients with bipolar disorder. Am J 
Psychiatry. 2017;174:795–802.
Sun YR, Herrmann N, Scott CJM, Black SE, Swartz RH, Hopyan J, Lanctôt KL. 
Lithium carbonate in a poststroke population: exploratory analyses of 
neuroanatomical and cognitive outcomes. J Clin Psychopharmacol. 
2019;39(1):67–71.
Tondo L, Abramowicz M, Alda M, Bauer M, Bocchetta A, Bolzani L, Calkin CV, 
Chillotti C, Hidalgo‑Mazzei D, Manchia M, Müller‑Oerlinghausen B, Murru 
A, Perugi G, Pinna M, Quaranta G, Reginaldi D, Reif A, Ritter P Jr, Ryba‑
kowski JK, Saiger D, Sani G, Selle V, Stamm T, Vázquez GH, Veeh J, Vieta E, 
Baldessarini RJ. Long‑term lithium treatment in bipolar disorder: effects 
on glomerular filtration rate and other metabolic parameters. Int J Bipolar 
Disord. 2017;5(1):27.
Tondo L, Alda M, Bauer M, Bergink V, Grof P, Hajek T, Lewitka U, Licht RW, 
Manchia M, Müller‑Oerlinghausen B, Nielsen RE, Selo M, Simhandl C, 
Baldessarini RJ, International Group for Studies of Lithium (IGSLi). Clinical 
use of lithium salts: guide for users and prescribers. Int J Bipolar Disord. 
2019;7(1):16.
Van Gestel H, Franke K, Petite J, Slaney C, Garnham J, Helmick C, Uher R, Alda 
M, Hajek T. Brain age in bipolar disorders: effects of lithium treatment. 
Aust N Z J Psychiatry. 2019;53(12):1179–88.
Velosa J, Delgado A, Finger E, Berk M, Kapczinski F, de Azevedo CT. Risk of 
dementia in bipolar disorder and the interplay of lithium: a systematic 
review and meta‑analyses. Acta Psychiatr Scand. 2020. https ://doi.
org/10.1111/acps.13153 .
Verdoux H, Quiles C, Bachmann CJ, Siskind D. Prescriber and institutional bar‑
riers and facilitators of clozapine use: a systematic review. Schizophr Res. 
2018;201:10–9.
Vieta E, Berk M, Schulze T, et al. Bipolar disorder. Nat Rev Dis Primers. 
2018;4:18008.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Cana‑
dian Network for Mood and Anxiety Treatments (CANMAT) and Interna‑
tional Society for Bipolar Disorders (ISBD) 2018 guidelines for manage‑
ment of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.
Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta‑anal‑
ysis on comparative efficacy and all‑cause discontinuation of antimanic 
treatments in acute bipolar mania. Psychol Med. 2014;45:299–317.
Zanni G, Goto S, Fragopoulou AF, Gaudenzi G, Naidoo V, Di Martino E, Levy G, 
Dominguez CA, Dethlefsen O, Cedazo‑Minguez A, et al. Lithium treat‑
ment reverses irradiation‑induced changes in rodent neural progenitors 
and rescues cognition. Mol Psychiatry. 2019. https ://doi.org/10.1038/
s4138 0‑019‑0584‑0.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
